Advertisement
Previous article
Psoriasis: Recognition and Management Strategies
Dec 2023
Next article
Preventing CVD in Women: Common Questions and Answers

Adnexal Masses: Diagnosis and Management

Vernon Wheeler, MD
Blade Umstead, DO
Christina Chadwick, DO, MS

American Family Physician. 2023;108(6):580-587.

Author disclosure: No relevant financial relationships.

Screening

History

Physical Examination

Evaluation

Management

Reference(s)

SORT: KEY RECOMMENDATIONS FOR PRACTICE

BEST PRACTICES IN GYNECOLOGY

Common Causes of Adnexal Mass

Sensitivity and Specificity of the Symptom Index for Ovarian Cancer

Reasons for Elevated Cancer Antigen 125 Levels Other Than Ovarian Cancer

Triple Screen Markers to Detect Ovarian Cancer in Patients With Adnexal Mass

FIGURE 1.
FIGURE 2.

Pelvic masses occur in up to 20% of women throughout their lifetime. These masses represent a spectrum of gynecologic and nongynecologic conditions. Adnexal masses—found in the fallopian tubes, ovaries, and surrounding areas—are mostly benign. Evaluation includes assessment for symptoms that may suggest malignancy, such as abdominal pain, abdominal bloating, and early satiety. A family history of ovarian, breast, or certain heritable syndromes increases the risk of malignancy. For women of reproductive age, ectopic pregnancies must be considered; a beta human chorionic gonadotropin level should be obtained. Transvaginal ultrasonography is the imaging test of choice for evaluating adnexal masses for size and complexity. Adnexal cysts that are greater than 10 cm, contain solid components, or have high color flow on Doppler ultrasonography are high risk for malignancy. Further imaging, if warranted, should be completed with computed tomography or magnetic resonance imaging, particularly if there is concern for disease outside the ovary. Multimodal assessment tools that use ultrasonography and biomarkers, such as the risk of malignancy index, are useful in the diagnosis and exclusion of malignant causes. Asymptomatic masses that are determined to be benign may be observed and managed expectantly. In symptomatic or emergent cases, such as ectopic pregnancy or ovarian torsion, a gynecologist should be consulted. In any adnexal mass with high risk for malignancy, a consultation with gynecologic oncology is indicated.

Pelvic masses occur in up to 20% of women during their lifetime and can arise from gynecologic or nongynecologic etiologies.1,2 The adnexa are a group of structures adjacent to the uterus, which includes the ovaries and fallopian tubes. Although the most common sources of adnexal masses are benign, such as luteal cysts and polycystic ovaries, masses can also have malignant causes, such as epithelial ovarian carcinoma or other cancers metastatic to the ovary. Potentially fatal adnexal masses include ectopic pregnancies, pelvic inflammatory disease, and tubo-ovarian abscesses3–6 (Table 14–7 ). This article reviews the evaluation and management of adnexal masses in women and other people assigned female sex at birth.

SORT: KEY RECOMMENDATIONS FOR PRACTICE

Clinical recommendation Evidence rating Comments
Screening for ovarian cancer is not recommended in asymptomatic women who are not at high risk.14 A U.S. Preventive Services Task Force recommendation statement based on consistent, large randomized controlled trials showing no mortality benefit and harm from frequent false-positive results
Transvaginal pelvic ultrasonography is the imaging test of choice for evaluation of adnexal masses.2 C Consensus statement based on equivalent sensitivity to computed tomography and magnetic resonance imaging
Patients with an adnexal mass who have an elevated cancer antigen 125 level, high-risk ultrasound findings, or any other concern for ovarian malignancy should be referred to a gynecologic oncologist.2 C Consensus, expert opinion
Asymptomatic and nonsuspicious adnexal masses found during pregnancy can be safely managed through observation because most of the masses self-resolve or regress and have low risk of malignancy.42,46 C Consensus, expert opinion and limited patient-oriented data

A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to https://www.aafp.org/afpsort.

BEST PRACTICES IN GYNECOLOGY

Recommendations From Choosing Wisely
RecommendationSponsoring organization
Do not screen for ovarian cancer in asymptomatic women at average risk.American College of Obstetricians and Gynecologists
Do not perform pelvic ultrasonography in average-risk women to screen for ovarian cancer.American College of Obstetricians and Gynecologists
Do not screen low-risk women with cancer antigen 125 levels or ultrasonography for ovarian cancer.Society of Gynecologic Oncology
Do not perform pelvic examination on asymptomatic nonpregnant women, unless necessary for guideline-appropriate screening for cervical cancer.American Academy of Family Physicians

Source: For supporting citations and to search Choosing Wisely recommendations relevant to primary care, see https://www.aafp.org/pubs/afp/collections/choosing-wisely.html.

Ovarian cancer is the second most common type of female reproductive cancer in the United States.8 Ovarian cancer causes 2.5% of all cancer in women and has a five-year survival rate of 50%.9,10 Survival rates are even lower among Black women, and, because these disparities persist after correcting for socioeconomic status, the rates may represent systemic racism.11,12

Screening

Screening for ovarian cancer is not recommended. The U.S. Preventive Services Task Force recommends against screening for ovarian cancer in asymptomatic women who are not high risk because of the lack of mortality benefit and high false-positive rates in randomized controlled trials evaluating the cancer antigen (CA) 125 level, transvaginal ultrasonography, and bimanual pelvic examination.13,14 The high false-positive rate can lead to significant harms, including unnecessary invasive procedures and postoperative complications.14 The American College of Physicians and the American Academy of Family Physicians recommend against pelvic examination screening.15–18 The U.S. Preventive Services Task Force found insufficient evidence to assess the balance of benefits and harms of screening with bimanual examinations in asymptomatic, nonpregnant patients.13

History

Adnexal masses can present with a variety of subtle symptoms. Abdominal and pelvic pain are the most common symptoms noted by premenarchal patients with an adnexal mass, including those with urgent etiologies.19 Common symptoms that are concerning for malignancy are vague, and the physician must maintain a high level of suspicion when evaluating women presenting with gastrointestinal symptoms such as early satiety, abdominal bloating, unintended weight loss, or urinary symptoms (e.g., frequency, urgency, incontinence). These symptoms, especially if present daily for more than two weeks or not responsive to appropriate treatment, should prompt further evaluation.20 If ovarian cancer is suspected, symptoms commonly associated with ovarian malignancy should be assessed (Table 23,21 ).

A review of risk factors can aid in diagnosis. Women of reproductive age should be assessed for pregnancy status and use of contraception; ectopic pregnancy presents as an adnexal mass that can be life-threatening. Special attention should be given to women with risk factors for ovarian malignancy, including nulliparity, delayed childbearing, unopposed estrogen, and obesity. A family history should be obtained, including history of ovarian or breast cancers or other heritable syndromes (e.g., Lynch syndrome) or the presence of BRCA mutation.22

Physical Examination

In patients with symptomatic or incidentally found adnexal masses, a physical examination may aid in detection of metastatic disease.2,15 However, in individuals with a body mass index greater than 30 kg per m2, identifying adnexal masses through physical examination has limited accuracy.2 Abdominal examination, which includes palpation for masses and assessment for ascites, can aid in detection of malignant disease.2 Auscultating and percussing the lungs to assess for consolidation or pleural effusion and evaluating lymph nodes may assist in detection of metastatic disease.2 A pelvic examination, including speculum, bimanual, and rectal examinations, may help characterize an adnexal mass. Any abnormalities on physical examination should be followed with imaging.

Evaluation

LABORATORY TESTING

In premenopausal patients, a serum or urine beta human chorionic gonadotropin (beta-hCG) level should be obtained in the initial evaluation of adnexal masses to assess for pregnancy-related conditions.2,23 A complete blood count with differential may indicate infectious etiologies (e.g., pelvic inflammatory disease, tubo-ovarian abscess, other inflammatory causes, including malignancy).2

Biomarkers. Although 80% of patients with epithelial ovarian cancers have elevated CA 125 levels, one-half of patients with stage 1 disease have normal levels.24 CA 125 testing has a high false-positive rate because elevated levels are associated with multiple conditions, including pregnancy, pelvic inflammatory disease, menstruation, and obesity25 (Table 33,25,26). In a woman with an adnexal mass and a CA 125 level greater than 35 U per mL (35 kU per L), the likelihood of a malignancy is 40% if she is postmenopausal and 13% if she is premenopausal.27

Human epididymis protein 4 (HE4) is elevated in 50% of patients who have ovarian cancer with normal CA 125 levels and is less frequently elevated in benign ovarian tumors and endometriosis.28 Normal values are not well established; therefore, HE4 is approved only in monitoring for recurrent or progressing epithelial ovarian cancers.28

Biomarker Panels. Panels that include multiple biomarkers, such as the risk for ovarian malignancy algorithm and multivariant index assay, are certified by the U.S. Food and Drug Administration for women 18 years and older who have an adnexal mass and in whom surgery is planned.2 The risk for ovarian malignancy algorithm uses serum concentrations of CA 125 and HE4 and also menopausal status to determine the likelihood of malignancy.28,29 The multivariant index assay uses five biomarkers associated with ovarian cancer to determine a malignancy risk score.30,31 Recent studies have shown that the second-generation multivariant index assay is superior to the risk for ovarian malignancy algorithm in detecting ovarian cancer.32,33

IMAGING

Transvaginal pelvic ultrasonography is the imaging test of choice for adnexal masses.2 In children and in adolescents who are not sexually active and do not use tampons, transabdominal ultrasonography may be more appropriate.34 Ultrasound findings that confer high risk for malignancy include a cyst (a specific type of adnexal mass) greater than 10 cm in diameter, papillary or solid components within a cyst, irregularity, high color flow on Doppler ultrasonography, or presence of ascites.2 Benign findings include cysts with thin, smooth walls and without solid components; septations; or internal blood flow on Doppler ultrasound imaging.2

Further imaging with computed tomography or magnetic resonance imaging may be indicated, particularly if there is concern for disease outside the ovary.16 Computed tomography or magnetic resonance imaging findings such as enlarged retroperitoneal lymph nodes, omental caking, and ascites should raise concern for ovarian malignancy.34–36

MULTIMODAL TOOLS

The risk of malignancy index and the International Ovarian Tumour Analysis’s assessment of different neoplasias in the adnexa (ADNEX) risk model use ultrasound findings and biomarkers to risk stratify women with adnexal masses. In women with suspected ovarian malignancy, the risk of malignancy index should be calculated, although utility is limited because of a sensitivity of 79% and specificity of 92%.37 The risk of malignancy index is available as an online calculator (https://www.mdcalc.com/calc/10103/risk-malignancy-index-rmi-ovarian-cancer).

Serum markers, including CA 125 and HE4, can be combined with a symptom index to evaluate higher risk of ovarian cancer. Although none of these scores rule out ovarian cancer, a low value may support continued close observation and follow-up.31 The symptom index was developed for use in primary care and comprises six symptoms (Table 2).3,21 The symptom index is considered positive if symptoms have been present at least 12 times per month for less than one year. Combining a symptom index with CA 125 and HE4 (triple screen) markers has higher specificity and positive predictive value than CA 125 alone, but the combination has similar sensitivity and negative predictive value for diagnosing ovarian cancer20,31 (Table 420,38 ). CA 125 combined with a positive symptom index has a high sensitivity (96.4%) and negative predictive value (97.4%), with specificity and positive predictive values of 65.5% and 57.8%, respectively; this demonstrates its clinical usefulness in areas where the HE4 assay may not be available or is cost prohibitive.21,38

TABLE 4. Triple Screen Markers to Detect Ovarian Cancer in Patients With Adnexal Mass

Marker(s)Sensitivity (%)Specificity (%)LR+LR−
CA 12579763.290.28
HE477918.560.25
SI + CA 12596.465.52.790.05
SI + CA 125 + HE479918.780.23

CA 125 = cancer antigen 125; HE4 = human epididymis protein 4; LR− = negative likelihood ratio; LR+ = positive likelihood ratio; SI = symptom index.

Information from references 20 and 38.

Management

PREMENARCHAL CHILDREN

Although one-half of adnexal masses in children are benign dermoid cysts, up to one-fourth of them are malignant.19,39 The most common type of malignancy in this age group is germ cell tumors, and laboratory testing that includes alpha feto-protein, beta-hCG, and l-lactate dehydrogenase levels should be obtained.2,40,41

Many adnexal masses in this age group can be managed expectantly if patients are asymptomatic and the masses appear benign on imaging. Indications for surgery include suspected torsion, persistent mass, concern for malignancy, or acute abdominal pain.4,42,43 If surgery is indicated, patients should be referred to a gynecologist, if possible, to also discuss ovarian-conserving management.39 If suspicion for ovarian malignancy occurs, a gynecologic oncologist should be consulted.2 Surgical planning should involve discussion of fertility preservation, and referral to a gynecologist or reproductive endocrinologist may be beneficial.44

NONPREGNANT ADOLESCENTS AND ADULTS WHO ARE OF REPRODUCTIVE AGE

Ruling out ectopic pregnancy should occur first in the evaluation of adnexal masses in all patients of reproductive age. Most pregnancies are visualized on transvaginal pelvic ultrasonography at a beta-hCG level of 1,500 mIU per mL (1,500 IU per L).23 Some intrauterine pregnancies may not be visualized at this cutoff, and patients can be monitored until they reach a beta-hCG level of 3,500 mIU per mL (3,500 IU per L) to avoid misdiagnosis of intrauterine pregnancy.23 If an intrauterine pregnancy is present, the risk for simultaneous ectopic pregnancy (heterotopic pregnancy) is extremely low, occurring in 1 in 30,000.45 If an ectopic pregnancy is diagnosed, consultation with a gynecologist is indicated.

After ectopic pregnancy is ruled out, malignancy should be considered. Referral to gynecologic oncology should occur with markedly elevated CA 125 levels, high-risk ultrasound imaging findings, nodular or fixed adnexal masses, or a high score on a risk evaluation tool.2 In apparently benign masses (e.g., physiologic cyst, endometrioma, mature teratoma), expectant management is appropriate with regular surveillance imaging. Guidelines on timing of follow-up imaging are lacking.2 The evaluation of adnexal masses in females of reproductive age is discussed in Figure 1.2,22,23,38

FIGURE 1.

Evaluation of adnexal masses in women of reproductive age.

Information from references 2, 22, 23, and 38.

PREGNANCY

Adnexal masses are discovered in up to 2.4% of pregnant patients.42 Although most masses in pregnant patients are benign or functional and can be observed throughout pregnancy, up to 5% are malignant.43 Up to 71% of ovarian masses either resolve or regress during pregnancy.46

In pregnant patients, adnexal masses are best characterized by ultrasonography. If additional imaging is warranted, magnetic resonance imaging is preferred.47 If a benign-appearing mass is detected during the first trimester, repeat imaging should occur between 18 and 20 weeks. Benign-appearing masses found in the second trimester should be further evaluated between 32 and 36 weeks, and those found in the third trimester can be evaluated during cesarean delivery (if obstetrically indicated) or six weeks postpartum.43

Surgical consultation is indicated if imaging findings suggest malignancy, the mass is increasing in size, the CA 125 level is markedly elevated (i.e., a CA 125 level greater than 35 U per mL [35 kU per L]), or the presentation suggests emergent conditions, such as ovarian torsion.42,43 Although surgery can be performed at any gestational age, the American College of Obstetricians and Gynecologists recommends nonurgent laparoscopic surgery be delayed to the early second trimester.48

PERIMENOPAUSAL AND POSTMENOPAUSAL ADULTS

Age is the most important risk factor for ovarian cancer. The median age of ovarian cancer diagnosis is 63 years, and 69% of cases are diagnosed at 55 years or older.2

Adnexal masses occurring in women 41 to 50 years of age are most often simple or functional cysts, whereas ovarian carcinomas most often occur in women older than 50 years.8 Any adnexal mass in this group should be evaluated using a CA 125 level and transvaginal ultrasonography. Simple cysts less than 5 cm in diameter have a low risk of malignancy, especially if asymptomatic and the serum CA 125 level is normal. These cysts typically have a physiologic cause and spontaneously resolve within six to 12 weeks.8

Endometriomas more commonly occur in perimenopausal women than in postmenopausal women, in which the risk of ovarian malignancy is three times higher.27 Dual screening using the symptom index and CA 125 level can help differentiate malignant from nonmalignant masses in perimenopausal women.

In perimenopausal women, the most common adnexal masses are functional ovarian cysts (corpus luteum cysts). In perimenopausal women, the CA 125 level is unreliable for excluding malignancy because of low specificity and frequent false-positive results. Transvaginal ultrasonography is most useful because a simple cyst makes CA 125 measurement unnecessary. Figure 2 shows the evaluation and recommended workup for adnexal masses in postmenopausal patients.2,8,27,37

FIGURE 2.

Evaluation of adnexal masses in postmenopausal women.

Information from references 2, 8, 27, and 37.

This article updates previous articles on this topic by Biggs and Marks3; Givens, et al.7; and Drake.49

Data Sources: A search was completed using PubMed, the Cochrane database, Essential Evidence Plus, and Google Scholar. The search included meta-analyses, randomized controlled trials, clinical trials, and reviews. Key search terms included adnexal mass, pelvic mass, ovarian cancer, ectopic pregnancy, CA 125, HER4, risk of ovarian malignancy, and risk of malignancy index. We critically reviewed studies that used patient categories such as race and gender but did not define how these categories were assigned. Search dates: October 1 to November 30, 2022, and November 2023.

The opinions and assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the U.S. Army, the U.S. Department of Defense, or the U.S. government.

Vernon Wheeler, MD, FAAFP, BCFMO, is co-director for the family medicine obstetrics faculty and research in the Carl R. Darnall Army Medical Center Family Medicine Residency Program, Fort Hood, Tex.; an assistant professor in the Department of Family and Community Medicine at the Uniformed Services University of the Health Sciences, Bethesda, Md.; and a clinical assistant professor at Texas A&M University Health Science Center College of Medicine, Temple, Tex.

BLADE UMSTEAD, DO, is a resident in the Carl R. Darnall Army Medical Center Family Medicine Residency Program.

CHRISTINA CHADWICK, DO, MS, RDMS, is family medicine faculty and the Point of Care Ultrasound (POCUS) Director in the Carl R. Darnall Army Medical Center Family Medicine Residency Program.

Address correspondence to Vernon Wheeler, MD, Carl R Darnall Army Medical Center, 36065 Santa Fe Ave., Fort Hood, TX 76544 (vernon.l.wheeler8.civ@health.mil). Reprints are not available from the authors.

Author disclosure: No relevant financial relationships.

  1. 1.Terzic M, Aimagambetova G, Norton M, et al. Scoring systems for the evaluation of adnexal masses nature: current knowledge and clinical applications. J Obstet Gynaecol. 2021;41(3):340-347.
  2. 2.American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins—gynecology. Practice bulletin no. 174: evaluation and management of adnexal masses. Obstet Gynecol. 2016;128(5):e210-e226.
  3. 3.Biggs WS, Marks ST. Diagnosis and management of adnexal masses. Am Fam Physician. 2016;93(8):676-681.
  4. 4.Smorgick N, Maymon R. Assessment of adnexal masses using ultrasound: a practical review. Int J Womens Health. 2014;6:857-863.
  5. 5.Baker M, dela Cruz J. Ectopic pregnancy, ultrasound. Updated January 16, 2023. Accessed October 4, 2023. https://www.ncbi.nlm.nih.gov/books/NBK482192/
  6. 6.Woźniak A, Woźniak S. Ultrasonography of uterine leiomyomas. Prz Menopauzalny. 2017;16(4):113-117.
  7. 7.Givens V, Mitchell GE, Harraway-Smith C, et al. Diagnosis and management of adnexal masses. Am Fam Physician. 2009;80(8):815-820.
  8. 8.Carvalho JP, Moretti-Marques R, Filho ALDS. Adnexal mass: diagnosis and management. Rev Bras Ginecol Obstet. 2020;42(7):438-443.
  9. 9.9. Ovarian Cancer Research Alliance. Stages of ovarian cancer. Accessed October 10, 2023. https://ocrahope.org/get-the-facts/statistics
  10. 10.Centers for Disease Control and Prevention. United States cancer statistics: data visualizations: ovary. November 2023. Accessed November 8, 2023. https://gis.cdc.gov/cancer/USCS/#/Survival/
  11. 11.Stewart SL, Harewood R, Matz M, et al. Disparities in ovarian cancer survival in the United States (2001–2009): findings from the CONCORD-2 study. Cancer. 2017;123(suppl 24):5138-5159.
  12. 12.Ross J, Braswell KV, Madeira da Silva L, et al. Unraveling the etiology of ovarian cancer racial disparity in the deep south: is it nature or nurture?. Gynecol Oncol. 2017;145(2):329-333.
  13. 13.Bibbins-Domingo K, Grossman DC, Curry SJ, et al. Screening for gynecologic conditions with pelvic examination: US Preventive Services Task Force recommendation statement. JAMA. 2017;317(9):947-953.
  14. 14.Grossman DC, Curry SJ, Owens DK, et al. Screening for ovarian cancer: US Preventive Services Task Force recommendation statement. JAMA. 2018;319(6):588-594.
  15. 15.Evans D, Goldstein S, Loewy A, et al. No. 385—indications for pelvic examination. J Obstet Gynaecol Can. 2019;41(8):1221-1234.
  16. 16.Bloomfield HE, Olson A, Greer N, et al. Screening pelvic examinations in asymptomatic, average-risk adult women: an evidence report for a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2014;161(1):46-53.
  17. 17.Saraiya M. Evidence is lacking to support pelvic examinations as a screening tool for non-cervical cancers or other conditions. Evid Based Med. 2015;20(1):31.
  18. 18.American Academy of Family Physicians. Clinical preventive service recommendation: screening pelvic exam. Accessed October 4, 2023. https://www.aafp.org/family-physician/patient-care/clinical-recommendations/all-clinical-recommendations/screening-pelvic-exam.html
  19. 19.Hermans AJ, Kluivers KB, Wijnen MH, et al. Diagnosis and treatment of adnexal masses in children and adolescents. Obstet Gynecol. 2015;125(3):611-615.
  20. 20.Goff BA, Mandel LS, Drescher CW, et al. Development of an ovarian cancer symptom index. Cancer. 2007;109(2):221-227.
  21. 21.Jain S, Danodia K, Suneja A, et al. Symptom index for detection of ovarian malignancy in Indian women: a hospital-based study. J Indian Acad Clin Med. 2018;19(1):27-32.
  22. 22.Salvador S, Scott S, Glanc P, et al. Guideline no. 403: initial investigation and management of adnexal masses. J Obstet Gynaecol Can. 2020;42(8):1021.e3-1029.e3.
  23. 23.Hendriks E, Rosenberg R, Prine L. Ectopic pregnancy: diagnosis and management. Am Fam Physician. 2020;101(10):599-606.
  24. 24.Sölétormos G, Duffy MJ, Othman Abu Hassan S, et al. Clinical use of cancer biomarkers in epithelial ovarian cancer: updated guidelines from the European Group on Tumor Markers. Int J Gynecol Cancer. 2016;26(1):43-51.
  25. 25.Funston G, Hamilton W, Abel G, et al. The diagnostic performance of CA125 for the detection of ovarian and non-ovarian cancer in primary care: a population-based cohort study. PLoS Med. 2020;17(10):e1003295.
  26. 26.Miralles C, Orea M, España P, et al. Cancer antigen 125 associated with multiple benign and malignant pathologies. Ann Surg Oncol. 2003;10(2):150-154.
  27. 27.Van Calster B, Valentin L, Van Holsbeke C, et al. A novel approach to predict the likelihood of specific ovarian tumor pathology based on serum CA-125: a multicenter observational study. Cancer Epidemiol Biomarkers Prev. 2011;20(11):2420-2428.
  28. 28.Janas Ł. Current clinical application of serum biomarkers to detect and monitor ovarian cancer—update. Prz Menopauzalny. 2021;20(4):211-216.
  29. 29.Chudecka-Głaz AM. ROMA, an algorithm for ovarian cancer. Clin Chim Acta. 2015;440:143-151.
  30. 30.Bristow RE, Smith A, Zhang Z, et al. Ovarian malignancy risk stratification of the adnexal mass using a multivariate index assay. Gynecol Oncol. 2013;128(2):252-259.
  31. 31.Dochez V, Caillon H, Vaucel E, et al. Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review. J Ovarian Res. 2019;12(1):28.
  32. 32.Dunton C, Bullock RG, Fritsche H. Multivariate index assay is superior to CA125 and HE4 testing in detection of ovarian malignancy in African-American women. Biomark Cancer. 2019;11 : 1179299X19853785.
  33. 33.Shulman LP, Francis M, Bullock R, et al. Clinical performance comparison of two in-vitro diagnostic multivariate index assays (IVDMIAs) for presurgical assessment for ovarian cancer risk. Adv Ther. 2019;36(9):2402-2413.
  34. 34.Kang GG, So KA, Hwang JY, et al. Ultrasonographic diagnosis and surgical outcomes of adnexal masses in children and adolescents. Sci Rep. 2022;12(1):3949.
  35. 35.Dodge JE, Covens AL, Lacchetti C, et al.; Gynecology Cancer Disease Site Group. Preoperative identification of a suspicious adnexal mass: a systematic review and meta-analysis. Gynecol Oncol. 2012;126(1):157-166.
  36. 36.Javadi S, Ganeshan DM, Qayyum A, et al. Ovarian cancer, the revised FIGO staging system, and the role of imaging. AJR Am J Roentgenol. 2016;206(6):1351-1360.
  37. 37.Royal College of Obstetricians and Gynaecologists. Management of suspected ovarian masses in premenopausal women. Green-top guideline no. 62; RCOG/BSGE joint guideline; November 1, 2011. Accessed October 4, 2023. https://www.rcog.org.uk/media/0mebp0mv/gtg_62.pdf
  38. 38.Krishnamurthy A, Durairaj J, Subbaiah M. Evaluation of a symptom-based score in combination with CA125 to predict ovarian malignancy in women with adnexal mass. J Egypt Natl Canc Inst. 2022;34(1):7.
  39. 39.Xac MC, Jetelina KK, Jarin J, et al. Benign, borderline, and malignant pediatric adnexal masses: a 10-year review. J Pediatr Adolesc Gynecol. 2021;34(4):454-461.
  40. 40.Gupta B, Guleria K, Suneja A, et al. Adolescent ovarian masses: a retrospective analysis. J Obstet Gynaecol. 2016;36(4):515-517.
  41. 41.Papic JC, Finnell SME, Slaven JE, et al. Predictors of ovarian malignancy in children: overcoming clinical barriers of ovarian preservation. J Pediatr Surg. 2014;49(1):144-147 , discussion 147–148.
  42. 42.Montes de Oca MK, Dotters-Katz SK, Kuller JA, et al. Adnexal masses in pregnancy. Obstet Gynecol Surv. 2021;76(7):437-450.
  43. 43.Martone S, Troìa L, Luisi S. Adnexal masses during pregnancy: management for a better approach. Gynecol Surg. 2021;18:3.
  44. 44.Practice Committee of the American Society for Reproductive Medicine. Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion. Fertil Steril. 2019;112(6):1022-1033.
  45. 45.Skrajna A, Cendrowski K, Alkhalayla H, et al. Heterotopic pregnancy. A case report. J Ultrason. 2012;12(50):342-348.
  46. 46.Condous G, Khalid A, Okaro E, et al. Should we be examining the ovaries in pregnancy? Prevalence and natural history of adnexal pathology detected at first-trimester sonography. Ultrasound Obstet Gynecol. 2004;24(1):62-66.
  47. 47.Committee on Gynecologic Practice Society of Gynecologic Oncology. Committee opinion no. 716: the role of the obstetrician–gynecologist in the early detection of epithelial ovarian cancer in women at average risk. Obstet Gynecol. 2017;130(3):e146-e149.
  48. 48.American College of Obstetricians and Gynecologists’ Committee on Obstetric Practice. ACOG Committee opinion no. 775: nonobstetric surgery during pregnancy. Obstet Gynecol. 2019;133(4):e285-e286.
  49. 49.Drake J. Diagnosis and management of the adnexal mass. Am Fam Physician. 1998;57(10):2471-2476.
Previous article
Psoriasis: Recognition and Management Strategies
Dec 2023
Next article
Preventing CVD in Women: Common Questions and Answers

Current issue

May 2026

May 2026

Copyright © 2026 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. See permissions for copyright questions and/or permission requests.